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Abstract
Purpose Sotatercept may represent a novel approach to the
treatment of chemotherapy-induced anemia (CIA). We report
the results from two phase 2 randomized studies examining
the use of sotatercept for the treatment of CIA in patients with
metastatic cancer.
Methods In study A011-08, patients with metastatic breast
cancer were randomized to 2:2:2:1 to receive sotatercept 0.1,
0.3, or 0.5 mg/kg, or placebo, respectively, every 28 days. In
study ACE-011-NSCL-001, patients with solid tumors treated
with platinum-based chemotherapy received sotatercept 15 or
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30 mg every 42 days. The primary endpoint for both studies
was hematopoietic response, defined as a hemoglobin (Hb)
increase of ≥1 g/dL from baseline.
Results Both studies were terminated early due to slow patient
accrual. Among patients treated with sotatercept in the A01108 and ACE-011-NSCL-001 studies, more patients achieved a
mean Hb increase of ≥1 g/dL in the combined sotatercept
0.3 mg/kg and 15 mg (66.7 %) group and sotatercept
0.5 mg/kg and 30 mg (38.9 %) group versus the sotatercept
0.1 mg/kg (0 %) group. No patients achieved a mean Hb
increase of ≥1 g/dL in the placebo group. The incidence of
treatment-related adverse events (AEs) was low in both studies, and treatment discontinuations due to AEs were
uncommon.
Conclusions Although both studies were terminated early,
these results indicate that sotatercept is active and has an acceptable safety profile in the treatment of CIA.
Keywords ActRIIA . Chemotherapy-induced anemia .
Erythropoiesis . Sotatercept

Introduction
Chemotherapy-induced anemia (CIA) is a common complication in patients treated with myelosuppressive chemotherapy
[1, 2]. Anemia is associated with fatigue, reduced functional
ability, and impaired quality of life [1, 3].
Current treatment options for CIA include red blood cell
(RBC) transfusions and erythropoiesis-stimulating agents
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(ESAs); however, both treatment types are associated with an
increased risk of thrombotic events [2]. In addition, ESAs may
be associated with possible decreased survival and shortened
time to tumor progression in patients with cancer, and RBC
transfusions carry a risk of infection, transfusion-related reactions, and possible decreased survival [2, 4–6]. Given these
safety concerns, novel treatment options for CIA that are efficacious and safe are needed.
Sotatercept (ACE-011) is a recombinant fusion protein
composed of the extracellular domain of the human activin
receptor type IIA (ActRIIA) and the fragment crystallizable
(Fc) domain of the human immunoglobulin G1 antibody [7].
Animal models and in vitro human models using RAP-011,
the murine ortholog of sotatercept, have shown that
sotatercept improves RBC parameters by stimulation of latestage erythropoiesis [7]. This mechanism of action is markedly different from that of ESAs, which act on earlier stages of
erythroid development [7, 8]. Sotatercept is thought to act by
trapping growth differentiation factor (GDF)-11, a ligand that
binds to ActRIIA and impedes terminal erythroid maturation
[7, 9]. A related ligand trap fusion protein, luspatercept (ACE536), has also been shown to promote maturation of late-stage
erythroid precursors via a similar pathway [10].
Administration of sotatercept or RAP-011 has been shown
to increase hemoglobin (Hb) and hematocrit levels in animal
models and in healthy postmenopausal women [7, 9, 11–14];
these findings have promoted interest in sotatercept as a potential treatment for patients with anemia and other diseases
characterized by ineffective erythropoiesis. In a mouse model
of CIA, RAP-011 has similar effects on Hb and hematocrit
[14].
Here we report the results from two phase 2 randomized
studies (A011-08 and ACE-011-NSCL-001) evaluating the
effects of sotatercept for the treatment of CIA. Studies
A011-08 and ACE-011-NSCL-001 were performed in patients with CIA, and both studies were of similar design.

Methods
Both studies were conducted according to good clinical practice and the ethical principles outlined in the 1964 Declaration
of Helsinki. All patients in both studies provided written informed consent prior to their inclusion in the studies.
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CIA in patients with advanced or metastatic solid tumors treated with platinum-based chemotherapy. Both trials are registered at www.ClinicalTrials.gov, A011-08 as NCT00931606
and ACE-011-NSCL-001 as NCT01284348. The data cutoff
dates for studies A011-08 and ACE-011-NSCL-001 were November 18, 2010 and January 29, 2013, respectively.
Adult patients with metastatic breast cancer who were undergoing treatment with a myelosuppressive chemotherapy
regimen, and who were expected to continue treatment for
≥9 weeks after initiation of study treatment, were eligible for
inclusion in study A011-08. Adult patients with solid tumors
and advanced or metastatic disease who were undergoing noncurative treatment with platinum-based chemotherapy were
eligible for inclusion in study ACE-011-NSCL-001.
Chemotherapies were administered according to the standard of care of each study site and included anthracycline,
taxane, gemcitabine, vinorelbine, or capecitabine. For both
studies, eligible patients were required to have a baseline Hb
level between ≥6.5 and <11.0 g/dL. Eligible patients were also
required to have had no ESA treatment in the previous 30 days
for study A011-08 or in the previous 28 days for study ACE011-NSCL-001. Patients were required to have received no
RBC transfusion in the previous 7 days for study A011-08
or in the previous 14 days for study ACE-011-NSCL-001.
Patients in both studies were required to have received ≤2 units
of transfused blood in the previous 30 days prior to study start.
Patients in study A011-08 who had received >5 prior chemotherapy regimens (not including the current regimen) were
excluded.
In study A011-08, patients were randomized to 2:2:2:1 to
0.1, 0.3, or 0.5 mg/kg sotatercept or to placebo, respectively;
treatment was administered subcutaneously every 28 days for
a maximum of four doses. Planned enrollment was 30 patients
to each of the three sotatercept treatment groups and 15 patients to the placebo group. In study ACE-011-NSCL-001,
patients were randomized to 15 or 30 mg of sotatercept, which
was administered subcutaneously every 42 days, for a maximum of four doses; the dose schedule was chosen based on
the onset and duration of Hb response to sotatercept in previous studies, as well as to accommodate common dosing
schedules for platinum-based chemotherapy. Planned enrollment was up to a maximum of 30 patients, with 10–15 patients
in each treatment group.
Analysis of studies

Study designs
A011-08 was a phase 2, double-blind, randomized, placebocontrolled study, which assessed the efficacy, safety, and tolerability of sotatercept for the treatment of CIA in patients
with metastatic breast cancer. ACE-011-NSCL-001 was a
phase 2a, open-label, randomized, dose-ranging study to evaluate the efficacy and safety of sotatercept for the treatment of

For this analysis, patients who were randomized to either
sotatercept 0.3 mg/kg in study A011-08 or sotatercept 15 mg
in study ACE-011-NSCL-001 have been included in a combined 0.3 mg/kg and 15 mg dose group based on an approximate body weight of 50–60 kg. Patients randomized to either
sotatercept 0.5 mg/kg in study A011-08 or sotatercept 30 mg
in study ACE-011-NSCL-001 have also been included in a
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combined sotatercept 0.5 mg/kg and 30 mg dose group. All
these dose levels were considered equivalent and combined
for analysis and reporting.

whereas patients in study A011-08 with an Hb concentration
above the upper limit of normal were discontinued from
treatment.

Dose modification

Study endpoints and definition of study population

Dose modification rules were based on Hb concentrations and
blood pressure readings since the last treatment (Fig. 1). Patients in study A011-08 were discontinued from treatment if
they experienced drug-related toxicity of grade ≥3, with the
exception of patients with grade 3 hypertension that had decreased to grade ≤1 within 7 days of receiving antihypertensive therapy. Patients in study ACE-011-NSCL-001 who experienced an Hb increase ≥3 g/dL sustained for a 28-day period received a dose reduction of two levels; of these patients,
those who experienced a second Hb increase of ≥3 g/dL were
discontinued from treatment. Patients in study ACE-011NSCL-001 were also discontinued from treatment if their
Hb increased to >15 g/dL, sustained for a 7-day period,

For study A011-08, the modified intent-to-treat (mITT) population and safety population included all randomized patients
who received ≥1 dose of study treatment. All analyses for
study ACE-011-NSCL-001 were performed on the population
of treated patients, defined as randomized patients who received ≥1 dose of sotatercept.
Per protocol, the primary endpoint for study A011-08 was
hematopoietic response (defined as an Hb increase from baseline of ≥1 g/dL for 28 consecutive days during the treatment
period and up to 2 months after the last dose of study treatment
in the absence of RBC transfusion or treatment with an ESA).
In study ACE-011-NSCL-001, efficacy was also assessed by
hematopoietic response, defined as an increase in Hb ≥1 g/dL

Fig. 1 Sotatercept dosemodification rules for studies
A011-08 and ACE-011-NSCL001. DBP diastolic blood
pressure, Hb hemoglobin, SBP
systolic blood pressure

A011-08: <2 g/dL increase within 28-day period since
last treatment day
ACE-011-NSCL-001: <2 g/dL increase within a dosing
period or a ≥2 g/dL increase not sustained for a 28-day
period since last dosing day
Hb <11 g/dL (per
local laboratory
value)

ACE-011-NSCL-001: <1 g/dL increase,
SBP <150 mmHg, DBP <100 mmHg

A011-08: ≥2 g/dL increase within 28-day period since
last treatment day
ACE-011-NSCL-001: ≥2 g/dL increase sustained for a
28-day period since last dosing day

Continue dosing

Dose escalation

Continue dosing,
with dose reduction

A011-08: <2 g/dL increase within 28-day period since last
treatment day
ACE-011-NSCL-001: <2 g/dL increase within a dosing
period or a ≥2 g/dL increase not sustained for a 28-day
period since last dosing day
Hb ≥11 g/dL (per
local laboratory
value)

A011-08: ≥2 g/dL increase within 28-day period since last
treatment day
ACE-011-NSCL-001: ≥2 g/dL increase sustained for a 28day period since last dosing day

Dose interruption

Dose interruption
followed by dose
reduction

A011-08: hypertension grade 2
ACE-011-NSCL-001: hypertension SBP ≥150 mmHg or
DBP ≥100 mmHg

A011-08: hypertension grade 3

Dose delay

Dose interruption,
followed by dose
reduction
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from baseline that was maintained for 4 consecutive weeks in
the absence of RBC transfusions and/or treatment with ESAs.
For this analysis, the proportion of patients achieving a mean
Hb increase from baseline of ≥1 g/dL is reported for the combined A011-08 and ACE-011-NSCL-001 study populations;
mean Hb increases were calculated from the first dose received until the end of the study period.
Secondary endpoints for study A011-08 included hematopoietic response (Hb increase of ≥2 g/dL and Hb concentration ≥11 g/dL sustained for 28 consecutive days), time to
achieve hematopoietic response, duration of hematopoietic
response, the proportion of patients requiring RBC transfusion
and/or treatment with an ESA, and safety. Exploratory endpoints for ACE-011-NSCL-001 included the evaluation of the
duration of hematopoietic response, assessment of renal function biomarkers, and evaluation of quality of life and bone
metabolism. Safety was evaluated in A011-08 using the safety
population, whereas all other secondary endpoints for A01108 were evaluated in the mITT population. Adverse events
(AEs) were recorded according to National Cancer Institute
Common Terminology Criteria for Adverse Events guidelines
version 3.0 and version 4.0 for the A011-08 and ACE-011NSCL-001 studies, respectively.

Results
Both studies were terminated early due to slower than expected patient accrual rates. Accrual rates were slower than expected due to recent substantial changes in the standard of care
for patients with cancer and anemia. Therefore, all analyses
presented are exploratory.
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Efficacy
Efficacy results are presented in Table 3. A mean Hb increase
of ≥1 g/dL was observed for 7 of 18 patients (38.9 %) in the
combined sotatercept 0.5 mg/kg and 30 mg dose groups, 16 of
24 patients (66.7 %) in the combined sotatercept 0.3 mg/kg
and 15 mg dose groups, 0 of 8 patients in the sotatercept
0.1 mg/kg dose group, and 0 of 5 patients treated with
placebo.
A mean increase in Hb levels ≥2 g/dL was observed in 2 of
18 patients (11.1 %) in the combined sotatercept 0.5 mg/kg
and 30 mg dose group, 2 of 24 patients (8.3 %) in the combined sotatercept 0.3 mg/kg and 15 mg dose group, 0 of 8
patients in the sotatercept 0.1 mg/kg dose group, and 0 of 5
patients treated with placebo (Fig. 2).
Of the 13 non-responders who received sotatercept in study
A011-08, 5 patients (38.5 %) had ≥1 dose interruption or
reduction. In four of these patients (80.0 %), an initial Hb
increase of ≥1 g/dL from baseline on or before day 29 had
been documented; however, following interruption/reduction
of the second sotatercept dose, the initial Hb increase was not
sustained. Mean Hb level increase following the first dose of
study treatment peaked at approximately 15 days after administration in the 0.3 and 0.5 mg/kg dose groups, before decreasing to near baseline levels by day 29.
Overall, 18 patients (36.0 %) administered sotatercept required either RBC transfusion or ESAs during the studies
reported herein: 9 patients (50.0 %) in the combined
sotatercept 0.5 mg/kg and 30 mg group, 8 patients (33.3 %)
in the combined sotatercept 0.3 mg/kg and 15 mg group, and 1
patient (12.5 %) patient in the sotatercept 0.1 mg/kg group.
Due to the small number of responses, median time to response was not evaluable.
Safety

Patients
Of 55 patients enrolled in the two studies, 5 patients received
placebo and 50 patients received ≥1 dose of sotatercept: 8
patients received sotatercept 0.1 mg/kg, 24 patients received
either sotatercept 0.3 mg/kg or 15 mg, and 18 patients received either sotatercept 0.5 mg/kg or 30 mg. A total of 30
patients were enrolled as part of study A011-08 and 25 patients were enrolled and received ≥1 dose of study treatment in
study ACE-011-NSCL-001.
Baseline characteristics are presented in Table 1. For patients treated with sotatercept, median age was 57 years
(range 22–81 years), 39 patients (78.0 %) were female,
and median Hb level at baseline was 9.0 g/dL (range 6.3–
11.0). Prior and concomitant antineoplastic use is presented
in Table 2; carboplatin was the most frequently administered concurrent chemotherapy regimen in patients treated
with sotatercept.

Of the 50 patients who received sotatercept, 10 (20.0 %) received the planned four doses of study drug: 2 patients
(11.1 %) in the combined 0.5 mg/kg and 30 mg dose groups,
7 patients (29.2 %) in the combined 0.3 mg/kg and 15 mg dose
groups, and 1 patient (12.5 %) in the 0.1 mg/kg dose group. A
further 8 patients (16.0 %) received three doses of sotatercept,
26 patients (52.0 %) received two doses, and 6 patients
(12.0 %) received one dose.
AEs were reported in 44 patients (88.0 %) and 5 patients (100 %) administered sotatercept and placebo, respectively (Table 4). Grade ≥3 AEs were reported in 35
patients (70.0 %) and 4 patients (80.0 %) administered
sotatercept and placebo, respectively. The most commonly
reported grade ≥3 AEs occurring in more than 10 % of
patients were anemia, neutropenia, and thrombocytopenia
in sotatercept-treated patients and neutropenia in placebotreated patients. One patient in the combined sotatercept
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Table 1 Baseline characteristics for patients with metastatic breast cancer (study A011-08 mITT population) and patients with advanced or metastatic
solid tumors (study ACE-011-NSCL-001)
Characteristic

Placebo
(n=5)

Sotatercept
Sotatercept 0.1 mg/kg
(n=8)

Age, median (range; years)

52 (32–61)

Female, n (%)
5 (100)
Hb level, median (range; g/dL)
9.9 (8.9–10.7)
Disease stage at diagnosis, n (%)

Sotatercept 0.3 mg/kg
and 15 mg (n=24)

Sotatercept 0.5 mg/kg
and 30 mg (n=18)

Total sotatercept
(N=50)

51 (38–70)

57 (22–81)

66 (35–80)

57 (22–81)

8 (100)
9.7 (7.5–11.0)

18 (75.0)
9.0 (6.3–11.0)a

13 (72.2)
8.8 (7.2–10.6)

39 (78.0)
9.0 (6.3–11.0)a

I
II

1 (20.0)
0

3 (37.5)
1 (12.5)

0
5 (20.8)

1 (5.6)
2 (11.1)

4 (8.0)
8 (16.0)

III

2 (40.0)

3 (37.5)

5 (20.8)

3 (16.7)

11 (22.0)

IV
Unknown

2 (40.0)
0

1 (12.5)
0

11 (45.8)
3 (12.5)

8 (44.4)
4 (22.2)

20 (40.0)
7 (14.0)

Breast
NSCLC

5 (100)
0

8 (100)
0

10 (41.7)
11 (45.8)

7 (38.9)
7 (38.9)

25 (50.0)
18 (36.0)

SCLC
Otherb

0
0

0
0

2 (8.3)
1 (4.2)

3 (16.7)
1 (5.6)

5 (10.0)
2 (4.0)

Malignancy, n (%)

Hb hemoglobin, mITT modified intent-to-treat, NSCLC non-small-cell lung cancer, SCLC small-cell lung cancer
a

Hb data are missing for one patient in the sotatercept 0.5 mg/kg and 30 mg dose group

b

Includes invasive malignant epithelioid mesothelioma (n=1) and adenocarcinoma (n=1)

Table 2 Summary of prior and concurrent antineoplastic therapy use in patients with metastatic breast cancer (study A011-08) and for patients with
advanced or metastatic solid tumors (study ACE-011-NSCL-001)
n (%)

Placebo
(n=5)

Sotatercept
Sotatercept 0.1 mg/kg
(n=8)

Sotatercept 0.3 mg/kg
and 15 mg (n=24)

Sotatercept 0.5 mg/kg
and 30 mg (n=18)

Total sotatercept
(N=50)

Carboplatin
Gemcitabine

0
1 (20.0)

1 (12.5)
3 (37.5)

12 (50.0)
5 (20.8)

7 (38.9)
6 (33.3)

20 (40.0)
14 (28.0)

Cisplatin
Paclitaxel
Doxorubicin
Bevacizumab
Pemetrexed
Etoposide
Docetaxel
Trastuzumab
Vinorelbine
Capecitabine
Cyclophosphamide
Fluorouracil
Mitomycin
Mitoxantrone
Tegafur
Vinblastine
Oxaliplatin

0
1 (20.0)
1 (20.0)
1 (20.0)
0
0
3 (60.0)
0
1 (20.0)
1 (20.0)
0
0
0
0
0
0
0

0
1 (12.5)
2 (25.0)
0
0
0
3 (37.5)
1 (12.5)
1 (12.5)
0
1 (12.5)
0
1 (12.5)
1 (12.5)
1 (12.5)
0
0

5 (20.8)
7 (29.2)
2 (8.3)
6 (25.0)
5 (20.8)
2 (8.3)
3 (12.5)
1 (4.2)
2 (8.3)
1 (4.2)
0
0
0
0
0
0
0

6 (33.3)
2 (11.1)
4 (22.2)
1 (5.6)
2 (11.1)
4 (22.2)
0
1 (5.6)
0
1 (5.6)
1 (5.6)
1 (5.6)
0
0
0
1 (5.6)
1 (5.6)

11 (22.0)
10 (20.0)
8 (16.0)
7 (14.0)
7 (14.0)
6 (12.0)
6 (12.0)
3 (6.0)
3 (6.0)
2 (4.0)
2 (4.0)
1 (2.0)
1 (2.0)
1 (2.0)
1 (2.0)
1 (2.0)
1 (2.0)

All patients had received prior or concurrent treatment with antineoplastic agents
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Table 3 Rates of hematopoietic responses among patients with metastatic breast cancer (study A011-08 mITT population) and patients with advanced
or metastatic solid tumors (study ACE-011-NSCL-001)
n (%)

Placebo
(n=5)

Sotatercept
Sotatercept 0.1 mg/kg
(n=8)

Sotatercept 0.3 mg/kg
and 15 mg (n=24)

Sotatercept 0.5 mg/kg
and 30 mg (n=18)

Total sotatercept
(N=50)

0
0

0
0

16 (66.7)
2 (8.3)

7 (38.9)
2 (11.1)

23 (46.0)
4 (8.0)

3 (60.0)

2 (25.0)

15 (62.5)

6 (33.3)

23 (46.0)

Hematopoietic response
Mean Hb increase ≥1 g/dL
Mean Hb increase ≥2 g/dL
Hb concentration ≥11 g/dL

Hb hemoglobin, mITT modified intent-to-treat

0.5 mg/kg and 30 mg dose groups reported a grade ≥3
thrombotic event (cerebrovascular accident). AEs related
to study treatment were reported in 11 patients (22.0 %)
treated with sotatercept.
Overall, 18 patients (36.0 %) died: 8 patients died in
the combined sotatercept 0.5 mg/kg and 30 mg dose
groups, 9 patients died in the combined sotatercept
0.3 mg/kg and 15 mg dose groups, and 1 patient died in
the sotatercept 0.1 mg/kg dose group; no patient died in
the placebo group. Cause of death was reported as disease
progression for 16 patients and unknown causes for 2
patients (a 57-year-old female in the combined 0.3 mg/kg
and 15 mg dose group and a 72-year-old female in the
combined 0.5 mg/kg and 30 mg dose group). Four deaths
occurred during the on-treatment period, all due to disease
progression; the remaining 14 deaths all occurred more
than 30 days after the last dose of sotatercept. No
treatment-related deaths were reported, and no AEs leading to death were considered study-drug-related.
Of the 50 patients who received sotatercept, 19
(38.0 %) had ≥1 dose interruption or reduction during
the study treatment period per protocol. A total of eight
patients (44.4 %) in the combined sotatercept 0.5 mg/kg
100

80

Placebo
66.7 %

Patients (%)

Fig. 2 Mean change in Hb level
from baseline for patients with
metastatic breast cancer (study
A011-08 mITT population) and
patients with advanced or
metastatic solid tumors (study
ACE-011-NSCL-001). Hb
hemoglobin, mITT modified
intent-to-treat

and 30 mg dose groups, seven patients (29.2 %) in the
combined sotatercept 0.3 mg/kg and 15 mg dose
groups, and four patients (50 %) in the 0.1 mg/kg dose
group had ≥1 dose interruption or reduction; a further
three patients (60.0 %) treated with placebo had ≥1
dose interruption or reduction. Dose delay or interruption due to AEs was experienced by three patients
(16.7 %) in the combined sotatercept 0.5 mg/kg and
30 mg dose group: one patient experienced thrombocytopenia, one patient experienced hypertension, and one
patient experienced pathologic fractures.
Treatment discontinuation as a result of AEs occurred
in eight patients (16.0 %) treated with sotatercept: six
patients in the combined 0.5 mg/kg and 30 mg dose
groups (metastatic breast cancer, tumor hemorrhage,
gastric ulcer perforation, pathological fracture, grade 3
muscular weakness, and grade 1 malignant mediastinal
neoplasm), one patient in the combined 0.3 mg/kg and
15 mg dose groups (grade 3 acute renal failure), and
one patient in the 0.1 mg/kg dose group (anemia)—
none was considered to be related to study treatment.
Treatment was discontinued for one patient (20.0 %)
treated with placebo (fatigue).

Sotatercept 0.1 mg/kg

60

Sotatercept 0.3 mg/kg and 15 mg
Sotatercept 0.5 mg/kg and 30 mg
38.9 %

40

20
8.3 %
0%

0%

0%

0%

0
≥1 g/dL

≥2 g/dL

Mean change in Hb level from baseline

11.1 %
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Table 4 AEs reported in patients with metastatic breast cancer (study A011-08) and for patients with advanced or metastatic solid tumors (study ACE011-NSCL-001)
n (%)

Placebo
(n=5)

Sotatercept
Sotatercept
0.1 mg/kg (n=8)

Sotatercept 0.3 mg/kg
and 15 mg (n=24)

Sotatercept 0.5 mg/kg
and 30 mg (n=18)

Total sotatercept
(N=50)

Patients with ≥1 AE

5 (100)

6 (75.0)

21 (87.5)

17 (94.4)

44 (88.0)

Patients with ≥1 AE related to treatmenta

1 (20.0)

2 (25.0)

5 (20.8)

4 (22.2)

11 (22.0)

Patients with ≥1 SAE
Patients with ≥1 AE grade ≥3

1 (20.0)
4 (80.0)

0
5 (62.5)

6 (25.0)
14 (58.3)

11 (61.1)
16 (88.9)

17 (34.0)
35 (70.0)

Grade ≥3 AEs occurring in ≥10 % of patients
Anemia
1 (20.0)
Neutropenia

1 (12.5)

5 (20.8)

6 (33.3)

12 (24.0)

3 (60.0)

4 (50.0)

2 (8.3)

6 (33.3)

12 (24.0)

Leukopenia

2 (40.0)

3 (37.5)

1 (4.2)

0

4 (8.0)

Thrombocytopenia
Asthenia

0
1 (20.0)

1 (12.5)
1 (12.5)

4 (16.7)
1 (4.2)

7 (38.9)
3 (16.7)

12 (24.0)
5 (10.0)

Dehydration
Febrile neutropenia
Fatigue

0
0
1 (20.0)

0
0
0

3 (12.5)
0
2 (8.3)

0
2 (11.1)
2 (11.1)

3 (6.0)
2 (4.0)
4 (8.0)

Hypomagnesemia
Non-small cell lung cancer

0
0

0
0

0
1 (4.2)

2 (11.1)
2 (11.1)

2 (4.0)
3 (6.0)

1 (20.0)

1 (12.5)

1 (4.2)

6 (33.3)

8 (16.0)

Patients with AEs leading to treatment
discontinuation
AE adverse event, SAE serious AE
a

Defined as possibly, probably, or definitely treatment-related, as assessed by the investigator

Discussion
Sotatercept has multiple direct and indirect hematologic effects that may contribute to its ability to improve the symptoms of anemia [15–18].
In a previous study of healthy postmenopausal women,
sotatercept administration was associated with marked increases in Hb, hematocrit, and RBC counts; sotatercept has
been suggested as a potential treatment for patients with ineffective erythropoiesis [13]. Furthermore, preliminary data
from another study have demonstrated evidence of sotatercept
activity in patients with β-thalassemia, a condition in which
ESAs are generally ineffective [8, 19]. These data suggest a
mechanism of action for sotatercept distinct from that of ESAs
and, therefore, raise the possibility of its use in other disease
areas.
The two phase 2 studies described herein evaluated
sotatercept as a potential treatment for CIA. The studies were
of a similar design, with similar endpoints, populations, and
dose-modification rules. A mean Hb increase from baseline of
≥1 g/dL was observed in 46 % of sotatercept-treated patients
with CIA, whether they had metastatic breast cancer (study
A011-08) or metastatic solid tumors (study ACE-011-NSCL001). Higher response rates were generally reported in the
combined sotatercept 0.3 mg/kg and 15 mg dose group and

the combined sotatercept 0.5 mg/kg and 30 mg dose group
versus the sotatercept 0.1 mg/kg group, suggesting a possible
dose–response relationship.
In both studies, sotatercept was well tolerated in patients
with CIA; safety findings were comparable to placebo and
were generally consistent with the disease under study [11,
13]. The incidence of treatment-related AEs was low in both
studies, and treatment discontinuations due to AEs were comparable to placebo. A single grade ≥3 thrombotic event was
reported in the combined sotatercept 0.5 mg/kg and 30 mg
dose group. Other treatment options for CIA, including ESAs
and RBC transfusion, are associated with an increased risk of
thrombotic events [2]. More deaths were reported in the
sotatercept treatment groups versus the placebo group; the
majority of deaths were due to disease progression. Given
the small number of patients in the placebo group, mortality
rates in the placebo and sotatercept treatment groups could not
be meaningfully compared. The generally favorable safety
profile of sotatercept highlights its potential as an alternative
to ESAs in the treatment of CIA. However, due to the small
number of patients enrolled and the limited follow-up data
available, it was not possible to assess the effect of sotatercept
on tumor progression.
There are several limitations to these studies. It is likely that
the dose-modification rules used may have resulted in patients
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who would otherwise have achieved a hematopoietic response
being categorized as non-responders; indeed, the majority of
patients who had a dose interruption or reduction in study
A011-08 achieved an initial Hb increase from baseline of
≥1 g/dL that was not sustained after dose modification.
Although the optimal dose and schedule of sotatercept for
the treatment of CIA has not been established, it is likely that
the dose scheduling employed in our studies may have affected outcomes. The two studies reported herein used dosing
intervals of 28 and 42 days, respectively; the dosing schedules
used were selected based on preliminary pharmacokinetics
and pharmacodynamics data from healthy volunteers treated
with sotatercept; mean terminal half-life after subcutaneous
multiple dose administration of sotatercept was approximately
23 days, and Hb increase was sustained until ≥2 months after
the last dose of sotatercept. Previous studies involving healthy
volunteers have also shown sustained Hb increases associated
with subcutaneous administration of sotatercept once every
28 days [13]. However, Hb increases peaked 15 days after
administration of the first dose of study treatment in study
A011-08, with a decrease to baseline levels by day 29, suggesting that the lack of a sustained Hb response may be due to
the dosing schedule used. Most patients in study ACE-011NSCL-001 had a hematological response, although responses
did not always meet study criteria and were not sustained.
These results suggest that shorter dosing intervals may be
beneficial in future studies.
Based on preliminary pharmacokinetics and pharmacodynamics data from healthy volunteers, the doses administered
in these studies did not exceed 0.5 mg/kg administered once
every 28 days. However, subsequent ongoing studies with
sotatercept have exceeded this dose: patients with anemia
are currently undergoing treatment with sotatercept
>1 mg/kg administered once every 3 weeks, with no doselimiting toxicities, and the maximum tolerated dose has not
yet been reached. It is possible, therefore, that the sotatercept
doses used herein may be beneath an optimal threshold.
The use of concomitant chemotherapy regimens was not
controlled for in either study and may have potentially affected study outcomes.
Both of the reported studies were terminated early due to
slow patient accrual as a result of significant changes in the
recommended treatment of CIA, as opposed to insufficient
efficacy or safety concerns. Consequently, the number of patients enrolled was small and the findings should be
interpreted with caution.
Despite these limitations, the available data provide insights into the potential clinical efficacy and safety of
sotatercept in the treatment of CIA. The results of these studies
indicate that sotatercept is active and has an acceptable safety
profile when used in the treatment of CIA. Furthermore, preliminary data from phase 2 trials of sotatercept for the treatment of anemia in patients with diseases characterized by
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ineffective erythropoiesis, including β-thalassemia and
myelodysplastic syndromes, are encouraging, further
supporting the clinical potential of sotatercept [19, 20].
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